Interestingly, a recent study demonstrated that an immune-related gene prognostic index constructed using SFRP4, CPXM1, and COL5A was associated with better survival and better responses to immune checkpoint inhibitor therapy for head and neck squamous cell carcinoma [37]. Here, CPXM1 is linked to head and neck squamous cell carcinoma.